Alentis Therapeutics Ag
Clinical trials sponsored by Alentis Therapeutics Ag, explained in plain language.
-
New drug ALE.P02 targets Tough-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced or spreading squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to find and attack cancer cells that have a specific protein (Claudin-1). The main goals are to check the d…
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New drug aims to shield kidneys from autoimmune attack
Disease control Recruiting nowThis study tests a new drug called ALE.F02 in people with ANCA vasculitis, an autoimmune disease that attacks small blood vessels, often damaging the kidneys. The goal is to see if adding ALE.F02 to standard treatment can protect kidney function and is safe. About 80 adults will …
Phase: PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, ALE.P03, that delivers a cancer-killing agent directly to tumor cells with a specific marker (CLDN1). It is for adults with advanced or metastatic cancers of the cervix, lung, colon, bile duct, or bladder that have not responded to standard treatments…
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 22, 2026 14:02 UTC